Sugi Predict

Sugi Predict / Compounds / SCHEMBL29445600

SCHEMBL29445600

SCHEMBL29445600

CC(C)(C)OC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ ITGB3 P05106 7/20 0.50
▸ ITGA2B P08514 7/20 0.50
▸ CTSS P25774 2/20 0.49
▸ CTSK P43235 2/20 0.49
▸ CPB1 P15086 1/20 0.48
▸ CPB2 Q96IY4 1/20 0.48
▸ CA1 P00915 3/20 0.47
▸ CA2 P00918 3/20 0.47
▸ SIRT6 Q8N6T7 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ SIRT5 Q9NXA8 1/20 0.43
▸ MAOA P21397 1/20 0.43
▸ MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758455 1.00 MEN1 (0.52) MEN1GAAKMT2AITGB3ITGA2B
SCHEMBL28799365 1.00 MEN1 (0.52) MEN1GAAKMT2AITGB3ITGA2B
SCHEMBL13702218 0.94 MEN1 (0.58) MEN1GAAKMT2ACTSSCTSK
SCHEMBL13702219 0.94 MEN1 (0.58) MEN1GAAKMT2ACTSSCTSK
SCHEMBL16389157 0.94 MEN1 (0.58) MEN1GAAKMT2ACTSSCTSK
SCHEMBL12192760 0.91 MEN1 (0.56) MEN1GAAKMT2ACTSSCTSK
SCHEMBL16351993 0.91 CAPN1 (0.53) MEN1GAAKMT2AITGB3ITGA2B
SCHEMBL30565192 0.91 ITGB3 (0.48) MEN1GAAKMT2AITGB3ITGA2B
SCHEMBL13997353 0.91 ITGB3 (0.48) MEN1GAAKMT2AITGB3ITGA2B
SCHEMBL30101985 0.90 MEN1 (0.64) MEN1GAAKMT2ACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492225-B2 Melanocyte-regulating peptides IDP DISCOVERY PHARMA, S.L. (ES) 2025-12-09 — — US disclosed
EP-4532513-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2025-04-09 — — EP disclosed
US-20240294573-A1 CONSTRAINED PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-09-05 — — US disclosed
US-20240083943-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2024-03-14 — — US disclosed
WO-2023227771-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2023-11-30 — — WO disclosed
EP-4271480-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2023-11-08 — — EP disclosed
CN-116964074-A Peptides that modulate VEGF IDP研发制药有限公司 2023-10-27 — — CN disclosed
CN-111263768-B anticancer peptides IDP研发制药有限公司 2023-10-13 — — CN disclosed
EP-3159352-B1 STITCHED POLYPEPTIDES HARVARD COLLEGE (US) 2023-08-02 — — EP disclosed
CN-109071622-B Peptides with anticancer activity IDP研发制药有限公司（ES） 2023-01-13 — — CN disclosed
US-20220306708-A1 BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-09-29 — — US disclosed
US-11440939-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-09-13 — — US disclosed
EP-4039698-A1 PEPTIDES WITH ANTI-CANCER ACTIVITY IDP Discovery Pharma, S.L. (ES) 2022-08-10 — — EP disclosed
WO-2022144401-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2022-07-07 — — WO disclosed
EP-4023295-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-07-06 — — EP disclosed
EP-4007563-A1 MELANOCYTE-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-06-08 — — EP disclosed
US-11352395-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-06-07 — — US disclosed
EP-3986914-A1 CONSTRAINED PEPTIDES TearSolutions, Inc. (US) 2022-04-27 — — EP disclosed
CN-114245800-A Melanocyte regulatory peptides IDP研发制药有限公司 2022-03-25 — — CN disclosed
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492225-B2 Melanocyte-regulating peptides MC1R, MITF, MCHR1 MEN1 292/4885GAA 3391/4885KMT2A 995/4885
US-11440939-B2 Anticancer peptides NGLY1, SLC1A5, SSTR5 MEN1 64/4885GAA 4697/4885KMT2A 2923/4885
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries TP53, MDM2, MDM4 MEN1 2384/4885GAA 3341/4885KMT2A 3182/4885
US-20240294573-A1 CONSTRAINED PEPTIDES IAPP, NGLY1, VIP MEN1 253/4885GAA 2628/4885KMT2A 4628/4885
US-11352395-B2 Anticancer peptides PNISR, NGLY1, SLC1A5 MEN1 77/4885GAA 4519/4885KMT2A 1904/4885
US-20220306708-A1 BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF TIMCC, CCL2, SGTA MEN1 567/4885GAA 3149/4885KMT2A 4278/4885
US-20240083943-A1 VEGF-REGULATING PEPTIDES VEGFA, FLT4, FLT1 MEN1 1193/4885GAA 4691/4885KMT2A 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.